← FDA DRUG APPROVALS

FDA ANDA · ANDA209543

BOSUTINIB

Sponsor: ALEMBIC

APPLICATION
ANDA209543
TYPE
ANDA
ORIGINAL APPROVAL
2025-05-23
LATEST ACTION
2025-05-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

BOSUTINIB MONOHYDRATEPrescription
BOSUTINIB MONOHYDRATE EQ 500MG BASE · TABLET · ORAL
BOSUTINIB MONOHYDRATEPrescription
BOSUTINIB MONOHYDRATE EQ 100MG BASE · TABLET · ORAL

Approval history

2026-06-12Manufacturing (CMC) · Supplement 1 · unknownTA
2025-05-23UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →